Hikma and US healthcare insurance provider Health Net have failed with early motions to dismiss Amarin’s induced infringement suit over Hikma’s generic rival to the originator’s Vascepa (icosapent ethyl), with a US court determining that Amarin has pleaded inducement claims that are “at least plausible.”
Following Hikma’s launch of the first US generic version of Vascepa in November last year following success in patent litigation,...




